March 2, 2018 / 8:37 AM / 5 months ago

BRIEF-Stada Says EMA Starts Evaluation Of Resubmitted Pegfilgrastim Application

March 2 (Reuters) - Stada:

* DGAP-NEWS: STADA ARZNEIMITTEL AG: EMA STARTED THE EVALUATION OF RESUBMITTED MARKETING AUTHORISATION APPLICATION FOR BIOSIMILAR PEGFILGRASTIM

* ‍EUROPEAN MEDICINES AGENCY (EMA) HAS ACCEPTED REGULATORY RESUBMISSION OF ITS PROPOSED BIOSIMILAR TO AMGEN’S NEULASTA​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below